In contrast to PYY, GLP-1 has been evaluated extensively in large clinical studies and serves as the foundation for several approved treatments for T2D and obesity, such as liraglutide and semaglutide. The gene discussed is PYY; the disease is obesity due to melanocortin 4 receptor deficiency.